Most Read Articles
19 Jun 2019
The choice between nonvitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) for stroke prevention appears to be complex and largely heterogenous across different, countries, a new study has found.
2 days ago
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Elvira Manzano, 2 days ago
Long-term treatment with the interleukin-5 receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.
Pearl Toh, 3 days ago
Emerging evidence is showing that the two major new classes of antidiabetic drugs — SGLT2* inhibitors and GLP-1** receptor agonists (RAs) — not only confer cardiovascular (CV) benefits to patients with type 2 diabetes (T2D), they also delay the loss of kidney function among these patients, potentially providing nephrologists with an additional tool in their armamentarium for managing patients with chronic kidney disease (CKD) in the future.

Functional vision, quality of life impaired in children with glaucoma

27 Jun 2017

A child’s functional visual ability (FVA) and quality of life (QoL) is greatly influenced by glaucoma and its management, according to a study.

In addition, the health-related (HR) QoL scores reported by children with glaucoma are similar to those stated by children with congenital cardiac defects, who have undergone liver transplants or who have acute lymphoblastic leukaemia.

In this cross-sectional, observational study, researchers recruited 119 children with glaucoma (mean age 9.4 years) and their parents to assess the effect of glaucoma on functional vision and on vision-related (VR) and HR QoL in children up to 16 years of age.

Participants completed three validated instruments: the Cardiff Visual Ability Questionnaire for Children (CVAQC) for FVA, the Impact of Vision Impairment for Children (IVI-C) for VR QoL, and the Pediatric Quality of Life Inventory (PEdsQL) version 4.0 for HR QoL.

Children with glaucoma reported reduced scores for FVA, VR QoL and HR QoL: median CVAQC score, ‒1.24 (interquartile range [IQR], ‒2.2 to ‒0.11; range, ‒3.00 higher visual ability to 2.80 lower visual ability); mean IVI-C score, 67.3 (standard deviation, 14.4; normal VR QoL, 96); median PedsQL self-report, 78.8 (IQR, 67.4 to 90.2); parent report, 71.2 (IQR, 55.7 to 85.8); and family impact score, 74.3 (IQR, 56.9 to 88.5; normal HR QoL, 100).

Moreover, psychosocial subscores were lower than physical subscores on the PedsQL. Compared with younger children, those who were older reported less impairment on CVAQC, IVI-C and PedsQL. Interestingly, parents reported greater impact on their child’s HR QoL than children reported themselves.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
19 Jun 2019
The choice between nonvitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) for stroke prevention appears to be complex and largely heterogenous across different, countries, a new study has found.
2 days ago
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Elvira Manzano, 2 days ago
Long-term treatment with the interleukin-5 receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.
Pearl Toh, 3 days ago
Emerging evidence is showing that the two major new classes of antidiabetic drugs — SGLT2* inhibitors and GLP-1** receptor agonists (RAs) — not only confer cardiovascular (CV) benefits to patients with type 2 diabetes (T2D), they also delay the loss of kidney function among these patients, potentially providing nephrologists with an additional tool in their armamentarium for managing patients with chronic kidney disease (CKD) in the future.